Suppliers / Derivados Quimicos SAU

Derivados Quimicos SAU

Spain Updated 9 July 2026

Derivados Quimicos SAU is an API manufacturer based in Spain. It holds 9 active US drug master files across a filed portfolio of 9 molecules. Its most recent recorded inspection, by US FDA, closed on 2 February 2023 as VAI.

9
active US DMFs
0
valid CEPs
1
registered plants 1 with an FDA FEI number
0
filings across 0 regulators
These figures were checked against the regulators' own files on 25 July 2026
Plants
1 of 1 confirmed
Inspections
4 of 4 confirmed
Sources: FDA Establishment Registration, read 4 May 2026. FDA drug inspection classifications, read 4 May 2026.

Inspection history

  • 2 February 2023 VAI US FDA
  • 14 June 2018 VAI US FDA
  • 23 October 2015 VAI US FDA
  • 15 November 2012 VAI US FDA

NAI means no action indicated, VAI means voluntary action indicated, and OAI means official action indicated.

Registered plants

Site FDA FEI
Spain, Spain 3003468553

What they file, and where

Molecule Regulators Docs
Meloxicam SFDA (Saudi Arabia), US FDA 2
Butoconazole US FDA 1
Cicletanine US FDA 1
Cyclobenzaprine US FDA 1
Fenofibrate US FDA 1
Ketoconazole US FDA 1
Milnacipran US FDA 1
Racepinephrine US FDA 1
Terconazole US FDA 1

Also appears on these molecule pages

Comparing suppliers?

Choose your molecules and target markets. Derivados Quimicos SAU comes back tiered against every other supplier able to file there.

Start for free
No sales call.

Open risk flags

  • The most recent inspection outcome was VAI, on 2 February 2023.

Sources on this page

FDA
Drug master files, establishment registration, inspection classifications
EDQM
Certificates of suitability